Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63% Increase Relative to Last Year
January 19 2022 - 8:00AM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solutions for visualization, interpretation
and reporting of genomic data, today announced the conclusion of
Bionano’s 2022 Symposium, with record daily attendance representing
a 63% increase relative to last year’s event. Bionano’s premier
scientific event showcasing OGM, Symposium was held January 10-13,
2022. Symposium had over 4,000 registrants from 82 countries and
featured 31 oral presentations and 37 scientific posters from
genomic scientists at leading institutions, including Brigham and
Women’s Hospital, MD Anderson Cancer Center, and Quest Diagnostics.
During this four-day online event, presenters reported on their use
of OGM and its utility for genetic disease and cancer applications.
“We were impressed by the engagement at 2022 Symposium and are
excited by the accomplishments of the genomic scientists from
around the world who presented their data,” commented Alka Chaubey,
PhD, FACMG, and Chief Medical Officer of Bionano. “Each presenter
showcased how OGM can outperform legacy techniques, resolve
decades-long questions in pathogenicity of genetic disease, and
complement multiple sequencing-based methods. We believe the record
attendance at this year’s Symposium speaks to the strong support
the research community has in pushing OGM workflows forward.”
Research shared over the four-day online event expanded on
several applications of OGM:
OGM can consolidate traditional cytogenetics techniques
into a single assay for genetic disease and cancer
applications.
- Accurate and higher resolution: Experts from
multiple leading institutions demonstrated concordance of OGM with
standard of care techniques and its ability to identify structural
variants relevant for patient stratification and disease
management.
- Cost-effective, scalable and fast turnaround
times: Compared to standard of care workflows, OGM can
provide laboratories with improved turnaround times and more
cost-efficient processing of specimens in a more scalable
approach.
- Simple and easy to implement workflow: For
genetic conditions and oncology studies where karyotype and
fluorescent in situ hybridization (FISH) are the current standard
of care, presenters demonstrated that OGM is ready for potential
implementation into routine genome analysis for a simpler workflow
than traditional techniques.
OGM can find more structural variants than traditional
methods and next-generation sequencing (NGS).
- OGM can provide answers in many clinical research areas where
structural variants have been overlooked or understudied as
contributors to genetic diseases and cancer.
- Examples described by presenters spanned a wide range of
disease areas including inherited retinal disease, high-risk breast
cancer, pulmonary mesothelioma, and pediatric brain tumors.
- The incremental variants OGM detects can help to improve
success rates for pathogenic variant finding and help solve
longstanding puzzles in genetic diseases and cancer.
OGM in combination with NGS can provide a comprehensive,
cost effective, scalable and accurate genome analysis.
- Presenters demonstrated that both sequence variants and
structural variants should be routinely considered in order to
capture the most comprehensive understanding of genetic variation
in human health.
- Combined, OGM and NGS workflows and visualization can enable
critical genetic discovery, as demonstrated by presentations on
OGM’s application in hematologic malignancies and developmental
disorders.
- Dr. Ravindra Kolhe, from the Medical College of Georgia at
Augusta University, presented on the benefits in combining OGM with
a 523-gene NGS panel (TSO500, Illumina) to reveal the comprehensive
structure of hematologic malignancy genomes. The combination
resulted in additional information beyond what a smaller 54-gene
panel, karyotype and FISH could detect, including single-nucleotide
variants (SNVs), copy number variants (CNVs) and
translocations.
OGM has additional potential applications in academic
and commercial laboratory settings.
- Presenters from AstraZeneca, bit.bio, and UTHSC (San Antonio)
shared how OGM can be used to assess the targeted integration of
foreign DNA in gene therapy, enhance quality control in pluripotent
stem cells, and evaluate the integrity of laboratory cell
lines.
- The sensitivity of OGM, including detection of genetic variants
at a single cell level, can provide a significant advantage for
these applications over competitive techniques.
“The scientific quality, global representation, and engagement
of researchers at this event was impressive,” commented Erik
Holmlin, PhD, President and Chief Executive Officer of Bionano. “I
would encourage anyone who was unable to attend live to login, view
these presentations and see how we are working to change the way
the world sees the genome through OGM.”
On-demand presentations are available with free registration at
https://www.labroots.com/ms/virtual-event/bngo2022.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that
can enable researchers and clinicians to reveal answers to
challenging questions in biology and medicine. The Company’s
mission is to transform the way the world sees the genome through
OGM solutions, diagnostic services and software. The Company offers
OGM solutions for applications across basic, translational and
clinical research. Through its Lineagen business, the Company also
provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. Through its BioDiscovery business,
the Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. For more information, visit
www.bionanogenomics.com, www.lineagen.com or
www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) convey uncertainty of future events or outcomes and
are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the clinical utility
of OGM in various research and clinical applications, including
treatment of cancer; the potential for OGM to replace or complement
current techniques in pathogenicity, pathogenic variant finding,
genetic diseases, targeted integration of foreign DNA, quality
control in pluripotent stem cells and integrity of laboratory cell
lines; and the ability for OGM to become part of the standard of
care and to provide additional applications in academic and
commercial laboratory settings. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape including the introduction of competitive technologies or
improvements in existing technologies; failure of future study
results to support those demonstrated during the presentations
referenced in this press release; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of our technologies; and the risks and
uncertainties associated with our business and financial condition
in general, including the risks and uncertainties described in our
filings with the Securities and Exchange Commission, including,
without limitation, our Annual Report on Form 10-K for the year
ended December 31, 2020 and in other filings subsequently made by
us with the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made and are based on management’s
assumptions and estimates as of such date. We do not undertake any
obligation to publicly update any forward-looking statements,
whether as a result of the receipt of new information, the
occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics,
Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2024 to May 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From May 2023 to May 2024